**Specifications table**TableSubject area*Cardiology*More specific subject area*Atrial fibrillation on stroke and mortality*Type of data*Tables and figures*How data was acquired*Data analysis from the National Health Insurance Research Database of Taiwan*Data format*Analyzed*Experimental factors*Atrial fibrillation patients receiving either rate or rhythm control strategy on cardiovascular outcome*Experimental features*Retrospective, observational, nationwide, and population-based cohort of patients with atrial fibrillation*Data source location*National Health Insurance Research Database of Taiwan*Data accessibility*The analyzed data is with this article.*Related research articleWeng CJ, Li CH, Liao YC, *et al.* Rhythm Control Better Prevents Stroke and Mortality than Rate Control Strategies in Patients with Atrial Fibrillation - A Nationwide Cohort Study. *Int J Cardiol* 2018 (in press) [@bib1]

**Value of the data**•This data provides the researchers to compare the different therapeutic strategies on cardiovascular outcomes in AF patients.•The data has a real-world long-term cardiovascular outcome in AF patients undergoing different control strategies.•Subgroup analysis data identifies risk factors contributing to favorable/detrimental outcomes in AF patients and helps to find out the patients at risk.

1. Data {#s0005}
=======

Taiwan National Health Insurance program started in 1995. In this program, over 99% of the Taiwanese population (\~23 million) is enrolled. The National Health Insurance Research Database of Taiwan includes records of outpatient visits, hospital admissions, prescriptions, and disease diagnoses, and is managed by the Taiwan National Health Research Institute (NHRI) [@bib2], [@bib3]. This data set contains AF patients retrieving from the National Health Insurance Research Database. AF patients receiving either rate or rhythm control strategies constitute the AF cohort (data set [Fig. 1](#f0005){ref-type="fig"}). The data of AF patients receiving rate versus rhythm control on major adverse cardiovascular event (MACE) stratified by CHA2DS2-VASc score is shown in [Fig. 2](#f0010){ref-type="fig"}. The medication data used in this AF cohort is shown in [Table 1](#t0005){ref-type="table"}. Subgroup analysis data of the hazard ratio for stroke and death in this AF cohort are shown in the data set [Table 2A](#t0010){ref-type="table"}, [Table 2B](#t0015){ref-type="table"}, respectively. The data of the hazard ratio for stroke, death and MACE by the rate/rhythm control duration is shown in [Table 3](#t0020){ref-type="table"}.Fig. 1Flow chart of the AF cohort. AF, atrial fibrillation; LHID, longitudinal health insurance database.Fig. 1Fig. 2The risk of stroke (A), mortality (B), and MACE (C) between rate and rhythm control groups in low (CHA2DS2-VASc score≤1), intermediate (CHA2DS2-VASc score=2), and high (CHA2DS2-VASc score≥3) risk patients. MACE, major adverse cardiovascular event. \* included ischemic and hemorrhagic stroke; \*\* included ischemic/hemorrhagic stroke and mortality.Fig. 2Table 1Medications used for rate and rhythm control in patients with AF.Table 1**MedicationsRate controlRhythm control*p*-Value*N* = 2196 (%)*N* = 654 (%)**Rate control β-blocker1404 (63.9)295 (45.1)\<0.0001 Diltiazem824 (37.5)127 (19.4)\<0.0001 Verapamil309 (14.1)59 (9.02)0.0007 Digoxin1507 (68.6)142 (21.7)\<0.0001Rhythm control Quinidine5 (0.76) Flecainide6 (0.92) Propafenone277 (42.4) Amiodarone481 (73.6) Sotalol9 (1.38)Cardiovascular medication ACEI/ARB1391 (63.3)299 (45.7)\<0.0001 α-blocker311 (14.2)87 (13.3)0.58 Diuretics1399 (63.7)255 (39.0)\<0.0001 Fibrates111 (5.05)29 (4.43)0.52 Statin296 (13.5)96 (14.7)0.43Anti-thrombotics Aspirin1393 (63.4)429 (65.6)0.31 Clopidogrel188 (8.6)74 (11.3)0.03 Warfarin420 (19.1)81 (12.4)\<0.0001[^1]Table 2ASubgroup analysis of the hazard ratio for stroke in AF patients.Table 2AVariableRate controlRhythm controlAdjusted HR (95% CI)*p*-Value*p* for interactionEventRateEventRateAge[a](#tbl2fna){ref-type="table-fn"}0.62 \<6513824.02713.30.65 (0.42--0.99)0.04 ≥6530545.75129.00.68 (0.50--0.92)0.01Sex[b](#tbl2fnb){ref-type="table-fn"}0.10 Female19936.53527.30.80 (0.56--1.16)0.24 Male24435.04317.20.60 (0.43--0.83)0.002CHA2DS2-VASc[c](#tbl2fnc){ref-type="table-fn"}0.99 ≤13217.71210.30.61 (0.31--1.20)0.15 26424.21216.30.66 (0.35--1.23)0.19 ≥334743.55428.70.66 (0.49--0.88)0.005Aspirin[d](#tbl2fnd){ref-type="table-fn"}0.70 No14930.72518.90.72 (0.46--1.10)0.13 Yes29438.95321.60.67 (0.49--0.90)0.007Clopidogrel[d](#tbl2fnd){ref-type="table-fn"}0.15 No41635.86819.60.65 (0.50--0.84)0.001 Yes2733.11032.60.91 (0.43--1.94)0.81Warfarin[d](#tbl2fnd){ref-type="table-fn"}0.89 No35435.46720.40.69 (0.53--0.91)0.007 Yes8936.71122.00.65 (0.35--1.23)0.19[^2][^3][^4][^5]Table 2BSubgroup analysis of the hazard ratio for death in AF patients.Table 2BVariableRate controlRhythm controlAdjusted HR (95% CI)*p*-Value*p* for interactionEventRateEventRateAge[a](#tbl3fna){ref-type="table-fn"}0.19 \<6517728.13315.60.67 (0.46--0.98)0.04 ≥6574710014574.70.82 (0.68--0.98)0.03Sex[b](#tbl3fnb){ref-type="table-fn"}0.005 Female38563.87755.30.95 (0.74--1.23)0.72 Male53969.610138.00.70 (0.57--0.87)0.002CHA2DS2-VASc[c](#tbl3fnc){ref-type="table-fn"}0.99 ≤14020.81815.00.83 (0.47--1.46)0.52 210135.02025.40.75 (0.47--1.22)0.25 ≥378387.414067.70.78 (0.65--0.93)0.006Aspirin[d](#tbl3fnd){ref-type="table-fn"}0.02 No32761.77251.30.96 (0.74--1.24)0.75 Yes59770.410640.00.74 (0.60--0.91)0.005Clopidogrel[d](#tbl3fnd){ref-type="table-fn"}0.26 No83764.815040.30.77 (0.64--0.92)0.004 Yes871022883.61.00 (0.64--1.55)0.99Warfarin[d](#tbl3fnd){ref-type="table-fn"}0.46 No75868.516045.50.85 (0.71--1.01)0.06 Yes16661.41833.70.60 (0.37--0.98)0.04[^6][^7][^8][^9]Table 3Hazard ratio for stroke, death and MACE by the rate/rhythm control duration.Table 3AF control StrategyAdjusted HR (95% CI)StrokeMortalityMACERate controlRefRefRefRhythm control30--179 cDDD0.74 (0.53--1.02)0.91 (0.74--1.13)0.93 (0.77--1.13)180--364 cDDD0.77 (0.54--1.12)0.73 (0.56--0.95)[\*](#tbl4fnStar){ref-type="table-fn"}0.79 (0.63--1.00)[\*](#tbl4fnStar){ref-type="table-fn"}≥365 cDDD0.34 (0.16--0.72)[\*](#tbl4fnStar){ref-type="table-fn"}0.68 (0.45--1.02)0.60 (0.41--0.87)[\*](#tbl4fnStar){ref-type="table-fn"}[^10][^11][^12]

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Research database {#s0015}
----------------------

The data set was created by a systemic randomized sampling of 1,000,000 patients from 1999 to 2010 in the National Health Insurance Research Database. This data set has been was confirmed to be representative of the general Taiwanese population. Since the patient׳s data was provided in an anonymous format, the written informed consents were waived. The creation of this data set was approved by the Institutional Review Board of Taichung Veterans General Hospital (CE13152B-4).

2.2. Patient population {#s0020}
-----------------------

To create the AF cohort data set, patients aged ≥ 18 years with a diagnosis of atrial flutter/fibrillation (AF), were identified by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes 427.3, 427.31, and 427.32. The diagnosis of AF was defined as three or more outpatient visits with a diagnostic code of AF within a year, or at least one hospitalization under an AF diagnostic code. The primary endpoints of the AF cohort were MACE, including hemorrhagic stroke (ICD-9-CM: 430-432), ischemic stroke (ICD-9-CM: 433--438), and death, therefore, patients were excluded from this cohort if they had experienced prior stroke or had died within one year of enrollment.

2.3. Definitions of medication use {#s0025}
----------------------------------

Patients who had used any one of the anti-arrhythmic drug (AADs) for AF rhythm control, and had a defined daily dose (DDD) of ≥30 within the first year of enrollment, were defined as the rhythm control group. The AADs and their classes for AF rhythm control included amiodarone (III), sotalol (III), propafenone (Ic), flecainide (Ic), quinidine (Ia), and procainamide (Ia). AF patients who received any rate control medications, including beta-blockers, calcium channel blockers (diltiazem, verapamil), and digitalis for ≥30 DDD within the first year of enrollment constituted the rate control group. Patients who used both rhythm and rate control medications were classified as the rhythm control group. AF treatment strategies in this cohort were chosen by physicians' clinical discretion. Current use was defined as taking medication between the prescription date and the end date of drug supply. Discontinuation was defined as when no medication was refilled after the end date of drug prescription. The data set also contains commonly prescribed antithrombotic therapies, including warfarin, acetylsalicylic acid, and clopidogrel for analysis.

2.4. Outcomes and covariates {#s0030}
----------------------------

The baseline demographic data was recorded. Cardiovascular co-morbidities including hypertension, hyperlipidemia, liver disease, diabetes mellitus (DM), coronary heart disease (CHD), congestive heart failure (CHF), peripheral vascular disease (PVD), valvular heart disease (VHD), chronic obstructive pulmonary disease (COPD), and chronic kidney disease (CKD) were identified by the ICD-9-CM diagnostic code if the patient had at least 1 hospitalization or 3 consecutive outpatient visits under the diagnosis of the above listed diseases.

2.5. Statistical analysis {#s0035}
-------------------------

Continuous variables were presented as mean ± standard deviations (SD), while proportions were used for categorical variables. Analysis of variance and Chi-square tests were used for comparing differences in the continuous and categorical variables. Multivariable Cox proportional hazard regression models were used to exclude confounding factors contributing to MACE occurrence (adjusted for age, gender, co-morbidities, and medications). A stratified analysis was used to evaluate the cardiovascular outcomes in patients with/without the specified medications. The rate control group served as the reference, and the occurrence of MACE in the rhythm control group was expressed by the hazard ratio (HR) and a 95% confidence interval (CI). All statistical analyses were carried out using SAS software version 9.2 (SAS Institute, Inc., Cary, NC, USA). A p value of \<0.05 was considered statistically significant.
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[^1]: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

[^2]: Model adjusted for sex, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease

[^3]: Model adjusted for age, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease

[^4]: Model adjusted for hyperlipidemia, COPD, CKD and liver disease

[^5]: Model adjusted for age, sex, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease

[^6]: Model adjusted for sex, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease.

[^7]: Model adjusted for age, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease.

[^8]: Model adjusted for hyperlipidemia, COPD, CKD and liver disease.

[^9]: Model adjusted for age, sex, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease.

[^10]: Model adjusted for age, sex, heart failure, hypertension, DM, hyperlipidemia, COPD, CKD, liver disease and peripheral vascular disease

[^11]: The duration of rate/rhythm control was stratified by cumulative defined daily doses (cDDDs) of the rate/rhythm control medication used.

[^12]: \<0.05
